Human IFN-gamma Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB2851

R&D Systems, part of Bio-Techne

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

CyTOF-ready, Immunocytochemistry, Intracellular Staining by Flow Cytometry, Neutralization

Cited:

Flow Cytometry, Immunohistochemistry-Frozen, Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 25723

View all IFN-gamma Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human IFN-gamma
Gln24-Gln166
Accession # AAP20098.1

Specificity

Detects human IFN-gamma in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse IFN-gamma, recombinant rat IFN-gamma, or recombinant porcine IFN-gamma is observed. Neutralizes the bioactivity of recombinant human IFN-gamma and will not neutralize the activity of rat or mouse IFN-gamma.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IFN-gamma Antibody

Detection of IFN- gamma antibody in Human PBMCs antibody by Flow Cytometry.

Detection of IFN- gamma in Human PBMCs by Flow Cytometry.

Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA, 1 ug/mL Ionomycin, and 3 uM Monensin overnight were stained with either (A) Mouse Anti-Human IFN- gamma Monoclonal Antibody (Catalog # MAB2851) or (B) Mouse IgG2B Isotype Control (Catalog # MAB0041) followed by anti-Mouse IgG PE-conjugated secondary antibody (Catalog # F0102B) and Mouse Anti-Human CD3 epsilon APC-conjugated Monoclonal Antibody (Catalog # FAB100A). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.
IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ gamma Antibody.

IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ gamma Antibody.

Recombinant Human IFN-gamma (Catalog # 285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (5 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human IFN-gamma Monoclonal Antibody (Catalog # MAB2851). The ND50 is typically 0.2-0.6 µg/mL.

Applications for Human IFN-gamma Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells stimulated with PMA and ionomycin 

Intracellular Staining by Flow Cytometry

0.25 µg/106 cells
Sample: Human peripheral blood mononuclear cells treated with PMA, Ionomycin, and Monensin fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012)

Neutralization

Measured by its ability to neutralize IFN‑ gamma inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M. J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND50) is typically 0.2-0.6 µg/mL in the presence of 5 ng/mL Recombinant Human IFN‑ gamma.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 2 reviews rated 4.5 using MAB2851 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-gamma

Interferon-gamma (IFN-gamma), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). It shares 90% amino acid (aa) sequence identity with rhesus IFN-gamma, 59-64% with bovine, canine, equine, feline, and porcine IFN‑ gamma, and 37-43% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (7).

References

  1. Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
  2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
  3. Gray, P.W. and D.V. Goeddel (1982) Nature 298:859.
  4. Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. USA 92:5401.
  5. Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
  6. Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
  7. McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. 20:125.
  8. Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. 3:1247.
  9. Kelchtermans, H. et al. (2008) Trends Immunol. 29:479.

Long Name

Interferon gamma

Alternate Names

IFG, IFI, IFNG, IFNgamma

Entrez Gene IDs

3458 (Human); 15978 (Mouse); 25712 (Rat); 396991 (Porcine); 281237 (Bovine); 403801 (Canine); 493965 (Feline)

Gene Symbol

IFNG

UniProt

AAP20098.1

Additional IFN-gamma Products

Product Documents for Human IFN-gamma Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human IFN-gamma Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.